Experimental drug combo targets Hard-to-Treat cancers
NCT ID NCT04491942
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This early-phase trial tests an experimental drug called BAY 1895344 combined with standard chemotherapy (cisplatin, with or without gemcitabine) in people with advanced solid tumors, especially urothelial cancer. The goal is to find the best dose and see how safe the combination is. About 74 participants will be enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BAY 1895344 (an experimental drug that blocks a protein called ATR, which cancer cells need to grow) combined with chemotherapy drugs cisplatin and gemcitabine
- What this could lead to
- If this works, it could point toward a new treatment option for advanced solid tumors, especially urothelial cancer, by making chemotherapy more effective.
- What could go wrong
- This is an early phase 1 trial with only 74 participants, so it is mainly looking for the right dose and safety. It may not show clear benefit, and combining drugs can increase side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BILE DUCT CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
New York, New York, 10032, United States
-
National Cancer Institute Developmental Therapeutics Clinic
Bethesda, Maryland, 20892, United States
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
University Health Network-Princess Margaret Hospital
Toronto, Ontario, M5G 2M9, Canada
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
-
University of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin, 53792, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Dual-Action antibody boost chemo against bile duct cancer?
- Can your own immune cells beat advanced cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Fasting during chemo: a new way to boost treatment?
- Can a protein calm the immune System's overreaction to cancer treatment?